“Points to Consider” for herbals
This article was originally published in The Tan Sheet
Executive SummaryQuality assurance, personnel/education, building/facilities, equipment, documentation are among issues addressed by European Agency for the Evaluation of Medicinal Products document released May 2. "Points to Consider on Good Agriculture & Collection Practice for Starting Materials of Herbal Origin," prepared by EMEA working group, also offers counsel on proper handling of: seeds/propagation material; cultivation; collection; harvest; primary processing; packaging; storage/distribution. Document carries no legal force as would GMP guidelines, but considerations "should be used as a basis for the establishment of such an appropriate quality assurance system," EMEA group says...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.